Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer.

Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer.

Phase I studies of [N-(2-hydroxypropyl)methacrylamide] (HPMA) copolymer-doxorubicin previously showed signs of activity coupled with 5-fold decreased anthracycline toxicity in chemotherapy-refractory patients. Here we report phase II studies using a similar material (FCE28068) in patients with breas...

ver descrição completa

Detalhes bibliográficos
Principais autores: Seymour, L, Ferry, DR, Kerr, D, Rea, D, Whitlock, M, Poyner, R, Boivin, C, Hesslewood, S, Twelves, C, Blackie, R, Schatzlein, A, Jodrell, D, Bissett, D, Calvert, H, Lind, M, Robbins, A, Burtles, S, Duncan, R, Cassidy, J
Formato: Journal article
Idioma:English
Publicado em: 2009

Registros relacionados